These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9784330)

  • 21. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
    Golaszewski T; Kölbl H; Lahousen M; Staab HJ
    Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
    Mabro M; Granisétron PK
    Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
    Hesketh PJ; Crews JR; Cohen R; Blackburn LM; Friedman CJ
    Cancer J; 2000; 6(3):157-61. PubMed ID: 10882331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
    Ozono S; Okajima E; Hirao YK; Natsume O; Kaneko Y; Ohara S; Tabata S; Watanabe S; Aoyama H; Sasaki K; Matsuki H; Takashima K; Maruyama Y; Yoshikawa M; Yamada K; Momose H; Hiramatsu T; Hayashi Y; Babaya K; Shiomi T
    Gan To Kagaku Ryoho; 1997 Feb; 24(3):349-56. PubMed ID: 9051139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
    Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
    J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
    Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
    J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
    Tsukuda M; Kohno H; Enomoto H; Kawai S; Yago T; Matsuda H; Ikema Y; Makino Y; Kubota A; Furukawa M
    Gan To Kagaku Ryoho; 1995 Sep; 22(10):1377-82. PubMed ID: 7668873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].
    Tanaka K; Sekine M; Serikawa T; Sanada H; Shichiri K; Fujimori R
    Gan To Kagaku Ryoho; 1998 May; 25(6):907-13. PubMed ID: 9617330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].
    Lehoczky O; Bagaméri A; Sárosi Z; Kulcsár T; Pulay T
    Orv Hetil; 2001 Aug; 142(31):1681-4. PubMed ID: 11556262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
    Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
    J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research
    J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery.
    White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T
    Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
    Hisano C; Nakano S; Okuma K; Masumoto N; Fujishima H; Nakamura M; Niho Y
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1175-81. PubMed ID: 8751806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.